Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Trial Profile

A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capmatinib (Primary) ; Digoxin; Rosuvastatin
  • Indications Adenocarcinoma; Bladder cancer; Colon cancer; Intestinal cancer; Liver cancer; Lung cancer; Malignant melanoma; Mouth neoplasm; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Rectal cancer; Renal cancer; Solid tumours; Uterine cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 09 Dec 2020 Results published in the British Journal of Clinical Pharmacology
    • 26 May 2017 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top